{"id":85234,"date":"2012-12-07T01:49:58","date_gmt":"2012-12-07T01:49:58","guid":{"rendered":"http:\/\/www.immortalitymedicine.tv\/uncategorized\/pharmacogenomics-in-rare-diseases-development-strategy-for-ivacaftor-video.php"},"modified":"2024-08-17T16:24:01","modified_gmt":"2024-08-17T20:24:01","slug":"pharmacogenomics-in-rare-diseases-development-strategy-for-ivacaftor-video","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/pharmacogenomics\/pharmacogenomics-in-rare-diseases-development-strategy-for-ivacaftor-video.php","title":{"rendered":"Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor&#8230; &#8211; Video"},"content":{"rendered":"<p><br \/>Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor...<br \/>...as a Therapy for Cystic Fibrosis Session 1: Pharmacogenomics: regulatory and methodological implications in early clinical development Speaker: Federico Goodsaid, Vertex Pharmaceuticals, USA Workshop on Pharmacogenomics: from science to clinical care (8 October 2012)From:emainfoViews:1    0ratingsTime:32:26More inScience   Technology<br \/><!-- Auto Generated --><\/p>\n<p>See the original post:<br \/>\n<a target=\"_blank\" href=\"http:\/\/www.youtube.com\/watch?v=RxUZh1bRevk\" title=\"Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor... - Video\" rel=\"noopener\">Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor... - Video<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor... ...as a Therapy for Cystic Fibrosis Session 1: Pharmacogenomics: regulatory and methodological implications in early clinical development Speaker: Federico Goodsaid, Vertex Pharmaceuticals, USA Workshop on Pharmacogenomics: from science to clinical care (8 October 2012)From:emainfoViews:1 0ratingsTime:32:26More inScience Technology  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/pharmacogenomics\/pharmacogenomics-in-rare-diseases-development-strategy-for-ivacaftor-video.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246862],"tags":[],"class_list":["post-85234","post","type-post","status-publish","format-standard","hentry","category-pharmacogenomics"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/85234"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=85234"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/85234\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=85234"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=85234"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=85234"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}